- Home
- APXT vs PRTA Comparison
APXT vs PRTA Comparison
Compare APXT & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APXT | PRTA |
|---|---|---|
| Founded | 2025 | 2012 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 457.8M | 482.3M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | APXT | PRTA |
|---|---|---|
| Price | $9.96 | $9.32 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 108.4K | ★ 416.4K |
| Earning Date | 01-01-0001 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $814,000.00 |
| Revenue This Year | N/A | $1,111.38 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.87 | $4.32 |
| 52 Week High | $10.00 | $14.34 |
Technical Indicators
Market Signals| Indicator | APXT | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 51.47 | 50.68 |
| Support Level | N/A | $8.23 |
| Resistance Level | N/A | $9.59 |
| Average True Range (ATR) | 0.03 | 0.50 |
| MACD | -0.00 | 0.06 |
| Stochastic Oscillator | 50.00 | 50.14 |
Price Performance
Historical ComparisonAbout APXT Apex Treasury Corporation Class A Ordinary Share
Apex Treasury Corp is a blank check company established for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.